<Anchor>
SK Bioscience, which is a consignment production of AstraZeneca vaccine, started subscription to general public offerings from yesterday (9th).
There is a high expectation that the stock price will rise a lot in the future as a vaccine-related stock, and as the subscription method has changed from this year, many people are rushing to subscription.
This is reporter Lim Tae-woo.
<Reporter>
There are enough customers to wait for more than an hour after picking up a waiting ticket at a brokerage branch.
[General Subscription Investor: When I read the newspaper, it was a prospect, and it was introduced like that.
So I tried it.]
On the first day of the subscription to SK Biosciences public offering stock, as investors continued to visit, 14 trillion won was collected as margin on the first day of subscription.
This is more than SK Biopharm and Big Hit Entertainment, which caused the subscription craze last year.
On the first day, the competition rate reached 76:1.
The more margins you pay, the more stocks you receive, but from this year on, half the amount allocated to the public offering is distributed equally regardless of the size of the margin, and it is possible to create multiple accounts and subscribe more than once, attracting more investors. .
[Kim Dong-woon/Head of NH Investment & Securities Center: Not only minors, but also fathers, mothers, grandchildren, etc. There are a lot of family units open, so if you do business with one person, you can open an account for up to an hour...
.]
The stock market is in an atmosphere that expects this subscription stock to record a very large return. Experts advise that it is necessary to prepare for large volatility given the recent contraction of the stock market and profit-taking offerings.